Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients.
COVID-19 vaccine
Chronic liver disease
SARS-CoV-2 vaccine
liver cirrhosis
Journal
Proceedings (Baylor University. Medical Center)
ISSN: 0899-8280
Titre abrégé: Proc (Bayl Univ Med Cent)
Pays: United States
ID NLM: 9302033
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
SARS-CoV-2 vaccinations were found to be highly effective in phase 3 clinical trials. However, these trials have not reported data regarding the subgroup of liver disease or excluded patients with liver disease. The effectiveness of COVID-19 vaccines among liver cirrhosis (LC) patients is unclear. We conducted this meta-analysis to assess the effectiveness of SARS-CoV-2 vaccination in LC patients. A comprehensive literature search was conducted to include all the relevant studies that compared the outcomes of LC patients who received SARS-CoV-2 vaccines vs. unvaccinated patients. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated by the Mantel-Haenszel method within a random-effect model. Four studies with 51,834 LC patients (20,689 patients received at least one dose vs 31,145 were unvaccinated) were included. COVID-19-related complications, including hospitalization (RR 0.73, 95% CI 0.59-0.91,
Identifiants
pubmed: 36876272
doi: 10.1080/08998280.2023.2165344
pii: 2165344
pmc: PMC9980592
doi:
Types de publication
Journal Article
Langues
eng
Pagination
151-156Informations de copyright
Copyright © 2023 Baylor University Medical Center.
Déclaration de conflit d'intérêts
The authors report no external funding or conflicts of interest.
Références
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Infect Dis Poverty. 2022 May 16;11(1):56
pubmed: 35578350
Res Synth Methods. 2010 Apr;1(2):97-111
pubmed: 26061376
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Clin Exp Hepatol. 2021 Nov-Dec;11(6):720-726
pubmed: 34177192
Hepatology. 2021 Aug;74(2):1049-1064
pubmed: 33577086
Hepatol Commun. 2022 Apr;6(4):889-897
pubmed: 34708575
J Hepatol. 2021 Apr;74(4):944-951
pubmed: 33563499
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Clin Gastroenterol Hepatol. 2022 Jan;20(1):162-172.e9
pubmed: 34509643
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):156-158
pubmed: 33444545
Hepatology. 2022 Jul;76(1):126-138
pubmed: 35023206
Stat Methods Med Res. 2018 Jun;27(6):1785-1805
pubmed: 27683581
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Gastroenterology. 2021 Nov;161(5):1487-1501.e5
pubmed: 34284037
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
JAMA. 2021 Nov 23;326(20):2043-2054
pubmed: 34734975
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
JAMA Intern Med. 2021 Oct 1;181(10):1306-1314
pubmed: 34254978
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):792-793
pubmed: 34043615
J Clin Transl Hepatol. 2017 Mar 28;5(1):50-58
pubmed: 28507927
Hepatology. 2023 Mar 1;77(3):834-850
pubmed: 36799617
Hepatology. 2021 Jul;74(1):322-335
pubmed: 33219546
Vaccines (Basel). 2022 Feb 28;10(3):
pubmed: 35335009
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120